Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors

Background This phase I study evaluated the safety and tolerability, pharmacokinetics and pharmacodynamics, immunogenicity, and antitumor activity of pembrolizumab in Japanese patients with advanced solid tumors. Methods Following an initial dose and a 28-day rest (cycle 1), pembrolizumab was admini...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimizu, Toshio, Seto, Takashi, Hirai, Fumihiko, Takenoyama, Mitsuhiro, Nosaki, Kaname, Tsurutani, Junji, Kaneda, Hiroyasu, Iwasa, Tsutomu, Kawakami, Hisato, Noguchi, Kazuo, Shimamoto, Takashi, Nakagawa, Kazuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2016
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859860/
https://www.ncbi.nlm.nih.gov/pubmed/27000274
http://dx.doi.org/10.1007/s10637-016-0347-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859860/
https://www.ncbi.nlm.nih.gov/pubmed/27000274
http://dx.doi.org/10.1007/s10637-016-0347-6

Ejemplares similares